Novo’s Liraglutide Gets Advisory Committee Review; Is Byetta To Blame?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA committee will discuss an NDA for the once-daily GLP-1 analogue March 2, likely pushing back the March 23 PDUFA date.
You may also be interested in...
Don’t Forget Injectable Insulin, Novo Nordisk Says
In the rush to develop new diabetes drugs, big pharma's focus has been mainly on anti-diabetic agents that prolong a patient's transition to insulin or on developing easier routes of administration for insulin that do away with the need for pesky needles
Don’t Forget Injectable Insulin, Novo Nordisk Says
In the rush to develop new diabetes drugs, big pharma's focus has been mainly on anti-diabetic agents that prolong a patient's transition to insulin or on developing easier routes of administration for insulin that do away with the need for pesky needles
Novo Nordisk Not Deterred By Regulatory Hurdles For Diabetes Drugs
FDA cardiovascular requirements for Victoza will be met post approval, management predicts.